Atria Wealth Solutions’s Passage Bio PASG Stock Holding History

Atria Wealth Solutions’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-500	Closed	-$5.67K	–	2030
2024 Q4	$5.67K	Buy	+500	New	+$6.51K	﹤0.01%	1962

Other funds holding PASG

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Atria Wealth Solutions's PASG Position: Q1 2025 in Review

Atria Wealth Solutions sold out of Passage Bio (PASG) in Q1 2025, closing a stake of 500 shares — an estimated $5.67K sold.

Atria Wealth Solutions first reported a position in PASG in Q4 2024 and held it in 1 quarter. The position peaked at $5.67K in Q4 2024. 41 funds tracked by Wall St. Rank hold PASG as of Q1 2025.

Atria Wealth Solutions reported no remaining Passage Bio position as of Q1 2025 after selling out during the quarter.
Atria Wealth Solutions sold 500 Passage Bio shares in Q1 2025, an estimated $5.67K.
Atria Wealth Solutions first reported a position in Passage Bio in Q4 2024 and held it in 1 quarter.
Atria Wealth Solutions's Passage Bio position peaked at $5.67K in Q4 2024.
41 funds tracked by Wall St. Rank held Passage Bio as of Q1 2025.

Based on Atria Wealth Solutions's 13F filing for Q1 2025, filed 9 May 2025.